Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 3, 2005
Last updated: May 15, 2017
Last verified: May 2017
The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget). This study will test the safety and efficacy of zoledronic acid in the prevention and treatment of corticosteroid induced osteoporosis in male and female patients.

Condition Intervention Phase
Drug: Zoledronic Acid
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (masked roles unspecified)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percent change in lumbar spine Bone Mineral Density at Month 12 relative to baseline.

Secondary Outcome Measures:
  • Percent change in lumbar spine Bone Mineral Density at Month 6 relative to baseline
  • Percent change in total hip, femoral neck, trochanter and distal radius Bone Mineral Density at Months 6 and 12 relative to baseline
  • Biochemical markers of bone turnover at Baseline, Day 10, Month 3, Month 6, Month 12
  • Overal safety of zoledronic acid compared to risedronate in patients receiving corticosteroid therapy

Estimated Enrollment: 802
Study Start Date: June 2004
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Long duration treatment with corticosteroids (started or ongoing)

Exclusion Criteria:

  • History of osteogenesis imperfecta, multiple myeloma or Paget's disease
  • History of Hyperparathyroidism, hyperthyroidism
  • History of Osteomalacia

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00100620

United States, Alabama
Center for Education and research on Therapeutics (CERTs) of Musculoskeletal Disorders
Birmingham, Alabama, United States, 35294-3708
United States, Georgia
United Osteoporosis Centers
Gainesville, Georgia, United States, 30501
United States, Maryland
Osteoporosis & Clinical Trials
Cumberland, Maryland, United States, 21502
United States, Ohio
University of Ohio
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Radiant Research
Wyomissing, Pennsylvania, United States, 19610
United States, Virginia
McGuire VA Medical Center
Richmond, Virginia, United States, 23249
Sponsors and Collaborators
Novartis Pharmaceuticals
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00100620     History of Changes
Other Study ID Numbers: CZOL446O2306
Study First Received: January 3, 2005
Last Updated: May 15, 2017

Keywords provided by Novartis:
Corticosteroid induced osteoporosis
zoledronic acid

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on May 24, 2017